New hope for rare blood disorder: dupilumab combo trial launches

NCT ID NCT06477653

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study tests whether adding dupilumab to standard treatment can help people with hypereosinophilic syndrome (HES) who still have symptoms despite current biologic therapy. About 30 adults will receive dupilumab injections for up to 48 weeks while continuing their usual medications. Researchers will track symptom changes and side effects to see if the combination offers better control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
dupilumab
What this could lead to
If it works, this could offer a new combination treatment to better control symptoms in people with hypereosinophilic syndrome who still have problems despite current therapy.
What could go wrong
This is a small early-phase pilot study with only 30 participants, so results may not apply broadly. Dupilumab can cause side effects like injection reactions or increased eosinophil counts, and it may not improve symptoms for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.